Product
Custirsen
Aliases
custirsen sodium
4 clinical trials
8 indications
Indication
Prostate CancerIndication
Breast CancerIndication
Bladder CancerIndication
Renal Cell CarcinomaIndication
lung cancerIndication
Ovarian CancerIndication
solid tumorIndication
Protocol SpecificClinical trial
A Randomized Phase II Study of OGX-011 in Combination With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients With Metastatic Hormone Refractory Prostate CancerStatus: Completed, Estimated PCD: 2007-11-08
Clinical trial
A Phase II Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination With Docetaxel in Advanced Breast CancerStatus: Completed, Estimated PCD: 2007-02-23
Clinical trial
A Phase I Study Of Combination Neoadjuvant Hormone Therapy And Weekly OGX-011 (Clusterin Antisense Oligonucleotide) Prior To Radical Prostatectomy In Patients With Localized Prostate CancerStatus: Completed, Estimated PCD: 2004-09-23
Clinical trial
A Phase I Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination With DocetaxelStatus: Completed, Estimated PCD: 2006-03-09